Open AccessColchicine (Myinfla)
Author(s) -
Reimbursement Team
Publication year - 2022
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2022.293
Subject(s) - medicine , coronary artery disease , colchicine , stroke (engine) , clinical trial , cardiology , coronary heart disease , quality of life (healthcare) , mechanical engineering , nursing , engineering
CADTH recommends that Myinfla should not be reimbursed by public drug plans for the reduction of atherothrombotic events in adults with coronary artery disease.
Evidence from 4 clinical trials in patients with coronary artery disease showed that adding Myinfla to standard preventive treatments lowered patients’ chances of having major cardiovascular events.
There was not enough evidence to show that Myinfla reduced mortality, heart attack and/or stroke, or improved health-related quality of life.